Verrica Pharmaceuticals announced the acceptance of an abstract that will feature clinical data from the Company’s ongoing Phase 2 study of VP-315 for the treatment of basal cell carcinoma, BCC. The presentation is titled “VP-315, an Investigational Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma”, and will highlight the antitumor activity of VP-315 as determined by clinical and histological clearance of treated BCC lesions from the Company’s ongoing Phase 2 trial. The data will be presented at the 2023 American Academy of Dermatology, AAD, Innovation Academy, which is being held from August 10-13, 2023, in Tampa, Florida.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRCA:
- Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting
- Biotech Alert: Searches spiking for these stocks today
- Verrica Pharmaceuticals price target raised to $12 from $11 at H.C. Wainwright
- Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
- Needham upgrades Verrica Pharmaceuticals to Buy on Ycanth opportunity